Type
|
Public |
---|---|
Traded as | NYSE: COO S&P 500 Component |
Industry | Medical Devices |
Predecessor | Martin H. Smith Co., Cooper Tinsley Laboratories, Inc. |
Founded | 1958 (1958) |
Founder | Martin H. Smith Co |
Headquarters | Pleasanton, California |
Area served
|
Worldwide |
Key people
|
Robert S. Weiss, CEO & Director |
Products | Contact lenses, medical products and equipment for treating women |
Revenue | US$1331 million (2011) |
Operating income
|
US$228 million (2011) |
Net income
|
US$175 million (2011) |
Total assets | US$2625 million (2011) |
Total equity | US$1937 million (2011) |
Number of employees
|
7400 (2011) |
Divisions | CooperVision (CVI), CooperSurgical (CSI) |
Website | www |
The Cooper Companies, Inc. is a US based, multinational company in the medical specialities sector. With its headquarters in Pleasanton, California, it has over 8,000 employees and consists of two subsidiaries, CooperVision (CVI) that provides contact lenses for both wearers and practitioners, and CooperSurgical (CSI) that provides products for health care professionals and establishments that are involved in women’s health care. Contact lens sales, in particular, soft toric lenses which correct astigmatism, make up for 80% of Cooper Company sales. Cooper Companies has manufacturing facilities in the UK, Puerto Rico and New York and distributes from Rochester, NY, Fareham, UK and Liege, Belgium, among many other smaller distribution locations.
Founded in 1958 by predecessor, Martin H. Smith Co, and then incorporated as Cooper Tinsley Laboratories, Inc. in 1961, the company changed its name to Cooper Laboratories Inc. in 1967. In 1979 Cooper Laboratories introduced their first soft contact lens in the United States. During a re-structuring in the 1980s, Cooper Laboratories was re-organised into three groups, CooperVision, CooperCare and CooperBiomedical, with a further group, Cooper Medical Devices Corp, added a year later. In 1987 the company adopted the name of Cooper Companies, with CooperVision existing as a subsidiary. By the 1990s, through various acquisitions and expansions, the company had expanded into other areas of healthcare, including, among others, medical devices and ophthalmic pharmaceuticals.
The President and Chief Executive Officer & Director is Robert S. Weiss'.
Mutual fund holders 62.21% Other institutional 34.90% Individual stakeholders 1.13%
2011 – Contact lenses from the Avaira line were recalled following an investigation by the United States Food and Drug Administration into claims that the level of silicone oil residue on the contact lenses could cause blurred vision and discomfort.
In 2012 Cooper Companies, Inc settled $27.0 million on a claim brought by a group of stockholders after claims that Cooper Companies misled them about the problems they were facing with contact lenses produced overseas, contact lenses that were subsequently recalled.
In 1988, Cooper Companies was involved in a case brought against them by Medical Engineering Corp, part of the Bristol-Myers Squibb Company, after they claimed that Cooper Companies had agreed to assume responsibility for breast implants that were manufactured while they still owned the business. This was one of many lawsuits related to breast implants and the issue was resolved in 1993 when Medical Engineering agreed to pay all legal costs relating to breast implants, both in the future and still in dispute.
CooperSurgical:
CooperVision:
Through its subsidiary, CooperVision, Cooper Companies is involved in various schemes and scholarship programmes in the UK, including the Park Sport initiative, a scheme run by Eastleigh Borough Council that offers different sporting activities to local families for free. It also hosts a Student Research Scholarship which encourages optometry students to take part in contact lens-based research projects.
Period | Date | Adjusted Actuals EPS | GAAP EPS |
---|---|---|---|
Q1 2023 | 2023-03-02 | Future report Set alerts | |
Q4 2022 | 2022-12-08 | 2.75 | 2.75 |
Q3 2022 | 2022-08-31 | 3.19 | 3.19 |
Q2 2022 | 2022-06-02 | 3.24 | 3.24 |
Q1 2022 | 2022-03-03 | 3.24 | 3.24 |
Q4 2021 | 2021-12-02 | 3.28 | 3.28 |
Q3 2021 | 2021-09-02 | 3.41 | 3.41 |
Q2 2021 | 2021-06-03 | 3.38 | 3.38 |
Q1 2021 | 2021-03-04 | 3.17 | 3.17 |
Q4 2020 | 2020-12-03 | 3.16 | 3.16 |
2016-06-30 | Boost Price Target | Stifel Nicolaus | Buy | $180.00 to $195.00 |
2016-06-25 | Reiterated Rating | Robert W. Baird | Outperform | $185.00 |
2016-06-04 | Reiterated Rating | Stephens | Hold | |
2016-06-04 | Reiterated Rating | Piper Jaffray | Buy | |
2016-06-04 | Reiterated Rating | Piper Jaffray Cos. | Buy | |
2016-06-03 | Reiterated Rating | Wells Fargo | Hold | |
2016-06-03 | Reiterated Rating | Wells Fargo & Co. | Hold | |
2016-06-02 | Reiterated Rating | Jefferies Group | Buy | $175.00 to $190.00 |
2016-05-16 | Upgrade | Cleveland Research | Neutral to Buy | |
2016-04-19 | Reiterated Rating | Robert W. Baird | Buy | |
2016-04-15 | Upgrade | Jefferies Group | Hold to Buy | $175.00 |
2016-03-05 | Reiterated Rating | Stephens | Hold | |
2015-12-17 | Initiated Coverage | Goldman Sachs | Neutral | $143.00 |
2015-12-17 | Initiated Coverage | Goldman Sachs Group Inc. | Neutral | $143.00 |
2015-12-07 | Reiterated Rating | Stifel Nicolaus | Buy | |
2015-12-05 | Reiterated Rating | Piper Jaffray | Buy | |
2015-12-04 | Lower Price Target | Robert W. Baird | Outperform | $171.00 to $155.00 |
2015-12-04 | Lower Price Target | Raymond James | Outperform | $168.00 to $155.00 |
2015-12-04 | Lower Price Target | KeyBanc | Overweight | $200.00 to $168.00 |
2015-12-04 | Lower Price Target | Jefferies Group | Hold | $170.00 to $136.00 |
2015-12-04 | Lower Price Target | BMO Capital Markets | $180.00 to $150.00 | |
2015-12-04 | Reiterated Rating | Piper Jaffray | Overweight | $205.00 to $145.00 |
2015-12-04 | Downgrade | JPMorgan Chase & Co. | Overweight to Neutral | $175.00 to $145.00 |
2015-12-04 | Lower Price Target | Raymond James Financial Inc. | Outperform | $168.00 to $155.00 |
2015-12-04 | Lower Price Target | KeyCorp | Overweight | $200.00 to $168.00 |
2015-12-01 | Lower Price Target | Stifel Nicolaus | Buy | $200.00 to $180.00 |
2015-11-23 | Reiterated Rating | Piper Jaffray | Buy | $212.50 to $205.00 |
2015-11-17 | Downgrade | Wells Fargo | Outperform to Market Perform | |
2015-10-09 | Lower Price Target | Robert W. Baird | Market Outperform | $195.00 to $171.00 |
2015-10-09 | Lower Price Target | BMO Capital Markets | $196.00 to $180.00 | |
2015-09-04 | Lower Price Target | Raymond James | $200.00 to $175.00 | |
2015-09-04 | Reiterated Rating | William Blair | Outperform | |
2015-09-04 | Reiterated Rating | BMO Capital Markets | Outperform | $204.00 to $196.00 |
2015-09-04 | Reiterated Rating | Piper Jaffray | Buy | $212.50 |
2015-08-27 | Reiterated Rating | Piper Jaffray | Overweight | $212.50 |
2015-08-26 | Upgrade | KeyBanc | Sector Weight to Overweight | $200.00 |
2015-06-06 | Reiterated Rating | Piper Jaffray | Overweight | $212.50 |
2015-06-05 | Boost Price Target | Oppenheimer | Market Perform | $178.00 to $182.00 |
2015-06-05 | Boost Price Target | Oppenheimer Holdings Inc. | Market Perform | $178.00 to $182.00 |
2015-03-31 | Boost Price Target | BMO Capital Markets | Outperform | $180.00 to $209.00 |
2015-03-25 | Boost Price Target | JPMorgan Chase & Co. | Overweight | $195.00 to $210.00 |
2015-03-19 | Initiated Coverage | Piper Jaffray | Overweight | $212.50 |
2015-03-06 | Boost Price Target | BMO Capital Markets | Outperform | $177.00 to $180.00 |
2015-03-06 | Boost Price Target | Oppenheimer | Market Perform | $170.00 to $178.00 |
2014-12-15 | Initiated Coverage | Oppenheimer | Market Perform | $170.00 |
2014-10-14 | Reiterated Rating | JPMorgan Chase & Co. | Neutral | $37.00 to $36.00 |
2014-09-12 | Reiterated Rating | JPMorgan Chase & Co. | Overweight | $180.00 to $195.00 |
2014-09-08 | Reiterated Rating | Jefferies Group | Hold | $135.00 to $170.00 |
2014-08-28 | Boost Price Target | Raymond James | Outperform | $160.00 to $175.00 |
2014-08-15 | Reiterated | Stifel | Buy | $150 to $180 |
2014-08-15 | Boost Price Target | Stifel Nicolaus | Buy | $150.00 to $180.00 |
2014-07-01 | Reiterated Rating | JPMorgan Chase & Co. | Overweight | $176.00 to $150.00 |
2014-06-06 | Reiterated Rating | JPMorgan Chase & Co. | Overweight | $140.00 to $150.00 |
2014-04-09 | Initiated Coverage | KeyBanc | Hold | |
2014-02-03 | Downgrade | Cleveland Research | Buy to Neutral | |
2014-01-07 | Downgrade | Citigroup Inc. | Neutral to Sell | $128.00 to $116.00 |
2013-12-06 | Reiterated Rating | Citigroup Inc. | Neutral | $133.00 to $128.00 |
2011-09-30 | Reiterated | Morgan Keegan | Outperform | $85 to $95 |
2011-08-11 | Initiated | William Blair | Outperform | |
2009-11-18 | Initiated | Morgan Keegan | Outperform | |
2009-03-04 | Reiterated | Jefferies & Co | Hold | $16 to $20 |
2008-05-12 | Initiated | Citigroup | Buy | |
2008-03-07 | Reiterated | BMO Capital Markets | Market Perform | $44 to $40 |
2008-02-14 | Downgrade | FTN Midwest | Buy to Neutral | |
2007-12-12 | Reiterated | Jefferies & Co | Hold | $46 to $41 |
2007-10-09 | Downgrade | JP Morgan | Neutral to Underweight | |
2007-10-04 | Downgrade | Bear Stearns | Peer Perform to Underperform | |
2007-09-07 | Upgrade | Citigroup | Hold to Buy | |
2007-08-23 | Initiated | Jefferies & Co | Hold | $48 |
2007-07-11 | Initiated | Wachovia | Mkt Perform | |
2007-05-21 | Upgrade | FTN Midwest | Neutral to Buy | |
2007-03-30 | Reiterated | Goldman Sachs | Buy | $54 to $56 |
2007-03-09 | Reiterated | Piper Jaffray | Market Perform | $47 to $51 |
2007-02-01 | Upgrade | Bear Stearns | Underperform to Peer Perform | $47.70 |
2016-06-30 | Boost Price Target | Stifel Nicolaus | Buy | $180.00 to $195.00 |
2016-06-25 | Reiterated Rating | Robert W. Baird | Outperform | $185.00 |
2016-06-04 | Reiterated Rating | Stephens | Hold | |
2016-06-04 | Reiterated Rating | Piper Jaffray | Buy | |
2016-06-04 | Reiterated Rating | Piper Jaffray Cos. | Buy |
There is presents forecasts of rating agencies and recommendations for investors about this ticker
In COO 393 funds of 2213 total. Show all
Fund name | Ticker shares |
---|---|
Vanguard Group, Inc | 5.49M |
BlackRock Inc. | 3.77M |
STATE STREET CORP | 2.15M |
Veritas Asset Management LLP | 2.05M |
JANUS CAPITAL MANAGEMENT LLC | 1.74M |
ALLIANCEBERNSTEIN L.P. | 1.58M |
BlackRock Institutional Trust Company, N.A. | 1.36M |
KAYNE ANDERSON RUDNICK INVESTMENT MANAGEMENT LLC | 1.28M |
GENERATION INVESTMENT MANAGEMENT LLP | 1.25M |
HENDERSON GROUP PLC | 1.25M |
JPMORGAN CHASE & CO | 1.11M |
BlackRock Fund Advisors | 1.04M |
VICTORY CAPITAL MANAGEMENT INC | 1.02M |
GEODE CAPITAL MANAGEMENT, LLC | 0.97M |
FIL Ltd | 0.93M |
Name Relationship | Total Shares | Holding stocks |
---|---|---|
WEISS ROBERT S President and CEO | 0.21% (99167) | ARAY / COO / |
KAUFMAN CAROL R Secretary, EVP, & CAO | 0.10% (45898) | CHDX / COO / NSP / |
PRESS DONALD | 0.09% (43970) | COO / |
White Albert G III VP Investor Rel., Treas. & CSO | 0.08% (37874) | COO / |
McBride Daniel G VP, General Counsel & CRO | 0.06% (30542) | COO / |
WEBER JOHN ARTHUR President, CooperVision, Inc. | 0.03% (15260) | COO / |
Matz Gregory W VP & CFO | 0.03% (15123) | COO / |
ROSENBERG STEVEN | 0.03% (12359) | BERK / COO / |
Lindell Jody S | 0.02% (11403) | COO / PDLI / |
BENDER A THOMAS | 0.02% (11205) | COO / |
PICHOTTA NICHOLAS J Pres, CEO Cooper Medical, Inc. | 0.02% (10697) | COO / |
ZINBERG STANLEY MD | 0.02% (9879) | COO / |
FOLDEN RODNEY VP & Corporate Controller | 0.02% (8592) | COO / |
KALKSTEIN MICHAEL | 0.02% (8320) | COO / |
RUBENSTEIN ALLAN E | 0.01% (5568) | COO / |
Golden Randal General Counsel | 0.01% (2885) | COO / |
Maloney Tina Corporate Controller | 0.01% (2874) | AMRS / COO / |
Andrews Brian G Treasurer | 0.01% (2642) | COO / |
Ricupati Agostino Sr. VP, Finance & Tax | 0.01% (2428) | COO / |